Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
Główni autorzy:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Format:	Artigo
Język:	angielski
Wydane:	2011
Dostęp online:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Predicting the outcome of ankylosing spondylitis therapy
od: Vastesaeger, Nathan, i wsp.
Wydane: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
od: Bert Vander Cruyssen, i wsp.
Wydane: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
od: van der Heijde, Désirée, i wsp.
Wydane: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
od: Désirée van der Heijde, i wsp.
Wydane: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
od: Braun, Jürgen, i wsp.
Wydane: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
od: Jürgen Braun, i wsp.
Wydane: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
od: Wagner, Carrie, i wsp.
Wydane: (2011)

Ankylosing spondylitis: an overview
od: Joachim Sieper, i wsp.
Wydane: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
od: Deodhar, Atul, i wsp.
Wydane: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
od: Atul Deodhar, i wsp.
Wydane: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
od: Braun, J, i wsp.
Wydane: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
od: Désirée van der Heijde, i wsp.
Wydane: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
od: Dominique Baeten, i wsp.
Wydane: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
od: Jürgen Braun, i wsp.
Wydane: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
od: Jürgen Braun, i wsp.
Wydane: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
od: Jürgen Braun, i wsp.
Wydane: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
od: Inman, Robert D., i wsp.
Wydane: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
od: Xenofon Baraliakos, i wsp.
Wydane: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
od: Braun, Jürgen, i wsp.
Wydane: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
od: Jürgen Braun, i wsp.
Wydane: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
od: Cruyssen, Bert Vander, i wsp.
Wydane: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
od: Bert Vander Cruyssen, i wsp.
Wydane: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
od: Annelies Boonen, i wsp.
Wydane: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
od: Braun, Jürgen, i wsp.
Wydane: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
od: Sambrook, Philip N., i wsp.
Wydane: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
od: Philip N. Sambrook, i wsp.
Wydane: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
od: Braun, Jürgen, i wsp.
Wydane: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
od: Zochling, J, i wsp.
Wydane: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
od: Désirée van der Heijde, i wsp.
Wydane: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
od: Ben A. C. Dijkmans, i wsp.
Wydane: (2009)

Ankylosing spondylitis: an overview
od: Sieper, J, i wsp.
Wydane: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
od: Sudha Visvanathan, i wsp.
Wydane: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
od: Braun, J, i wsp.
Wydane: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
od: Jürgen Braun, i wsp.
Wydane: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
od: Davis, J C, i wsp.
Wydane: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
od: Désirée van der Heijde, i wsp.
Wydane: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
od: Braun, J, i wsp.
Wydane: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
od: Désirée van der Heijde, i wsp.
Wydane: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
od: Vosse, D, i wsp.
Wydane: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
od: Jürgen Braun, i wsp.
Wydane: (2016)